Treatment of early-stage chronic venous disease – management standards for 2023

Chronic venous disease (CVD) is one of the most prevalent diseases in the world. Most patients with early-stage CVD will eventually deteriorate, which will result in an increase in treatment costs, but most importantly, a decrease in quality of life. The advances made with regard to the knowledge of the natural history and pathophysiology of CVD as well as the results of research on effects of different drugs depending on the severity of the disease suggest the likely cost-effectiveness of CVD patients being treated at an early stage of the disease. Recommendations in this group of patients may include lifestyle changes, compression therapy and venoactive drugs (VADs). Combination of ruscus, hesperidin methyl chalcone, and vitamin C is a well-established VAD presenting with anti-inflammatory effects, reducing endothelial activation and leukocyte adhesion, increasing capillary resistance and integrity and improving venous tone and performance of the lymphatic vessels thus leading to a reduction in CVD symptoms in patients and an improvement in quality of their lifes. This article is based on the latest guidelines regarding the management of chronic venous disease.